

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07672 A2

- (51) International Patent Classification⁷: A61K (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/US00/42625
- (22) International Filing Date: 7 December 2000 (07.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/619,183 19 July 2000 (19.07.2000) US
- (71) Applicant: AEROPHARM TECHNOLOGY, INC.
[—/US]; Raritan Center, Campus Plaza, 18 Mayfield Avenue, Edison, NJ 08837 (US).
- (72) Inventors: ADJEI, Akwete, L.; 15 Tillman Court, Bridgewater, NJ 08807 (US). CUTIE, Anthony, J.; 10 Tillman Court, Bridgewater, NJ 08807 (US).
- (74) Agent: ROSENSTOCK, Jerome; Frommer Lawrence & Haug LLP, 745 Fifth Avenue, New York, NY 10151 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/07672 A2

(54) Title: A MEDICINAL AEROSOL FORMULATION

(57) Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, or combination of at least two particulate drugs a propellant and a stabilizing agent comprising a water addition.

A MEDICINAL AEROSOL FORMULATION

RELATED APPLICATIONS

This application is a continuation-in-part of application USSN 09/209,228, filed December 10, 1998, now pending, herein incorporated by
5 reference.

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to a medicinal aerosol formulation, and more particularly, to a medicinal aerosol formulation comprising a stabilizer comprising a
10 water addition.

Description of the Related Art

Delivery of drugs to the lung by way of inhalation is an important means of treating a variety of conditions, including such common local conditions as bronchial asthma and chronic obstructive pulmonary disease and some systemic
15 conditions, including hormone replacement, pain management, cystic fibrosis, etc. Steroids, β_2 agonists, anticholinergic agents, non-steroidal antiinflammatory agents, proteins and polypeptides are among the drugs that are administered to the lung for such purposes. Such drugs are commonly administered to the lung in the form of an aerosol of particles of respirable size (less than about 10 μm in diameter). The
20 aerosol formulation can be presented as a liquid or a dry powder. In order to assure proper particle size in a liquid aerosol, as a suspension, particles can be prepared in respirable size and then incorporated into the suspension formulation containing a propellant. Alternatively, formulations can be prepared in solution form in order to avoid the concern for proper particle size in the formulation. Solution formulations
25 must nevertheless be dispensed in a manner that produces particles or droplets of respirable size.

Once prepared an aerosol formulation is filled into an aerosol canister equipped with a metered dose valve. In the hands of the patient the formulation is dispensed via an actuator adapted to direct the dose from the valve to the patient.

30 It is important that an aerosol formulation be stable such that the pressurized dose discharged from the metered dose valve is reproducible. Rapid creaming, settling, or flocculation after agitation are common sources of dose

irreproducibility in suspension formulations. This is especially true where a binary aerosol formulation containing only medicament and propellant, e.g. 1,1,1,2-tetrafluoroethane, is employed or where such formulation contains small amounts of surfactant as well. Sticking of the valve also can cause dose irreproducibility. In order to overcome these problems aerosol formulations often contain surfactants, which serve as suspending aids to stabilize the suspension for a time sufficient to allow for reproducible dosing. Certain surfactants also function as lubricants to lubricate the valve to assure smooth actuation. Myriad materials are known and disclosed for use as dispersing aids in aerosol formulations. Suitability of materials, however, is dependent on the particular drug and the propellant or class of propellant used in the formulation.

It is sometimes difficult to dissolve sufficient quantities of conventional surfactants in hydrofluorocarbon (HFC) propellants such as HFC-134a and HFC-227. Cosolvents, such as ethanol, have been used to overcome this problem, as described in U.S. Patent No. 5,225,183. An alternative approach that avoids cosolvents involves materials that are soluble in hydrofluorocarbon propellants and are said to be effective surfactants or dispersing aids in an aerosol formulation. Among such materials are certain fluorinated surfactants and certain polyethoxysurfactants.

It is known in the art that the presence of water in conventional aerosol formulations often result in a number of potential problems, e.g. stability of the formulation, erratic dose delivery, and, in some cases free radical reactions in the propellant. Therefore, it has generally been accepted that these preparations should be maintained substantially free of water. The rigorous exclusion of atmospheric moisture during both the manufacture and storage of such formulations, referred to as "developed" or "nascent" formulation water, increases the difficulties of preparing satisfactory stable aerosols containing the drug and raises the overall cost of the final product, especially when a moisture barrier, e.g. foil pouching, is included as a secondary package.

An exception had been found for beclomethasone dipropionate monohydrate. It has been reported that a formulation of this particular medicament

combined with an amount of water in addition to its water of hydration is stable. In this regard, reference is made to U.S. Patent No. 5,695,744.

What has not been appreciated, however, is that despite all efforts an amount of water develops in medicinal aerosol formulations during processing of such formulations which can not be eliminated and is always present ("developed" or "nascent" formulation water). Most surprising and unexpected is that such unstable formulations, containing nascent formulation water, can be and are stabilized by the presence of a concentration of water added in addition to the nascent or developed formulation water which stabilizes such medicament formulations, and where such concentration of water addition is much less than that required by the beclomethasone dipropionate monohydrate formulations reported in U.S. Patent No. 5,696,744.

SUMMARY OF THE INVENTION

It has surprisingly been found that novel medicinal aerosol formulations can be obtained without the use of either cosolvents, such as ethanol, or surfactants, such as sorbitan trioleate which are added to a binary aerosol formulation. Stable medicinal aerosol formulations are obtained by the use of a water addition.

DETAILED DESCRIPTION OF THE INVENTION

This invention involves a stable suspension aerosol formulation suitable for pressurized delivery which comprises (1) a particulate medicament or drug or combination of at least two medicaments or drugs, (2) a suitable propellant, and (3) a stabilizer comprising a water addition.

A suitable medicament or drug is one which is suitable for administration by inhalation, the inhalation being used for oral and nasal inhalation therapy. Therapeutic categories of drugs or medicaments include cardiovascular drugs, antiallergics, analgesics, bronchodilators, antihistamines, antitussives, antifungals, antivirals, antibiotics, pain medicaments, anti-inflammatories, peptides, proteins and steroids.

Particularly suitable medicaments or drugs include albuterol (also known as salbutamol), atropine, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol,

prednisolone, mometasone, triamcinolone acetonide, salmeterol, amiloride, fluticasone esters, such as phosphate, monohydrate and furoate, (-)-4-amino-3,5-dichloro- α -[[[6(2-pyridinyl)ethoxy] hexyl] amino] methyl]benzene-methanol. Also included are the suitable acid addition salts of the foregoing drugs, their hydrates and their other solvates. In this regard, suitable acid addition salts include the salts obtained from inorganic acids, such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids as well as organic acids such as tartaric, citric, acetic, succinic, maleic, fumaric and oxalic acids. Suitable pharmaceutically acceptable solvates include solvates with ethylactate, alkanes, ethers, alcohols and water.

A preferred embodiment of this invention are aerosol formulations which provide for a combination of at least two and most preferably not more than four different medicaments such as cardiovascular drugs, antiallergenics, analgesics, bronchodilators, antihistamines, antitussives, antifungal, antiviral, antibiotics, pain medicaments, anti-inflammatories, peptides, proteins and steroids and of the use of these aerosol formulations to treat the disease states associated with these medicaments. These medicaments and their use to treat a particular disease state are well known to a practitioner of the art.

Especially preferred, are formulation which comprise combinations comprising at least two different medicants, such as β_2 -adrenergic agonists, corticosteroids, anticholinergics and leucotriene modulators. Especially preferred are β_2 -adrenergic agonists, such as albuterol and formoterol and corticosteroids, such as mometasone, hydrocortisone, fludrocortisone, dexamethasone, prednisone, cortisone, aldosterone hemi-acetal, betamethasone, beclomethasone dipropionate, triamcinolone acetonide, budesonide dipropionate, fluticasone propionate and flunisolide, anticholinergics, such as ipratropium bromide, histamine antagonists (mast cell modulators), such as cromolyn and non-steroidal antiinflammatory agents, such as acetaminophen or ibuprofen.

This invention includes the derivatives of the foregoing medicaments. These derivatives include all the salt, ester, solvate and hydrate forms of the foregoing drugs as well as their geometric and optical isomers, including their chiral forms. Such derivatives are well known to a practitioner in this art.

The leucotrienes contemplated in this invention are those which are implicated as mediators of allergic and inflammatory responses associated with bronchial asthma and rheumatoid arthritis. These medicaments are known in the art to constrict dramatically the pulmonary airways and small blood vessels. Thus, inhibitors or antagonists of leucotrienes are effective mediators of the allergic responses typified by asthma and may be used to treat bronchial asthma and other diseases states associated with inflammation of the airways.

The leucotriene modulators contemplated in this application include, but not limited to the following:

1. Inhibitors or antagonists of leucotriene, including the PAF receptor antagonists and 5-lipoxygenase inhibitors, for example 2,5-diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines, triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds, 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines (see, U.S. Patent Nos. 5,856,323; 5,358,938; 4,959,361; and 3,987,052), including, both optically pure and racemates (U.S. Patent No. 5,629,337). An example of this group of compounds is Zileuton® (Abbott Laboratories) and Acolate® (Merck).
2. Chromone-2-carboxylic acid derivatives as antagonists of SRS-A (slow reacting substance of anaphylaxis (see, Samuelsson et al., Department of Chemistry, Karolinska Institutet, Stockholm, Sweden, TIPS, 227, May, 1980; J. Med. Chem. 20 371 (1977)), such as 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylate (FPL 55712),

which is a specific antagonist of SRS-A as well as a standard for evaluating other inhibitors;

- 5 3. Aryloxyalkyloxy-and aralkyloxy-4-hydroxy-3-nitrocoumarins as antagonists of SRS-A and inhibitors of histamine release, (see. e.g. Buckle et al., J. Med. Chem. 22 158 (1979); U.S. Patent No. 4,296,237; European Patent No. 0036663; U.S. Patent No. 4,296,120; and U.S. Patent No. 4,296,129), as well as
10 other compounds which act as inhibitors of SRS-A including oxiranbutyric acid esters, 3-hydroxy-4-substituted-3-pyrroline-2,5-diones or carboxy-oxo-pyrrolidino)phenyl alkenamides and esters or
15 (carboxyacylamino)phenyl alkenamides and esters, or the substituted derivatives of these before mentioned compounds, including, but not limited, to alkyl, hydroxy amino, dialkylamino, hydroxymethyl, aminomethyl, alkylaminomethyl or alkanoylaminomethyl of 1 to 12 carbon atoms; -CN, -CONH₂ or -CO₂M in which M is
20 hydrogen, aryl, phenyl, or naphthyl, cyclohexyl, cyclopentyl, or fluoromethoxy; or
4. Antagonists and inhibitors of leukotriene including N-o-tolylsulfonylbenzamide compounds.

25

All of the aforementioned prior literature is expressly incorporated by reference. These medicaments are known in the art to treat inflammatory diseases and include medicaments that block the release, production, secretion, or any other biochemical action arachidonic acid, prostaglandins and thromboxanes, or other leukotrienes
30 that participate in inflammatory reactions, exhibit chemotactic activities, stimulate lysosomal enzyme release and act as important factors in the immediate hypersensitivity reaction.

Especially preferred medicaments include groups comprising [1-formyl-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-(hydroxycarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-((2-carboxyethyl)carbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-((2-tetrazolylethyl)carbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-(methylphenylcarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-(diphenylcarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide; [1-carbamoyl-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, and [1-(pyrrolidine-carbonyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide. Also, pharmaceutically acceptable salts of these agents, including addition salts derived from organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methane sulfonic, nitric, p-toluene sulfonic, acetic, citric, maleic, succinic acid and the like. In addition, the compounds in their free carboxylic acid form may be converted by standard techniques well-known to the practitioner to their corresponding alkali metal (e.g. sodium or potassium), alkaline earth metal (e.g. calcium or magnesium), ammonium or primary, secondary and tertiary alkylamine salts, the latter containing from 1 to 6 carbon atoms in their alkyl moieties or a pharmaceutically acceptable salt thereof. These components are known in the literature and are described, for example in Brown et al., J. Med. Chem., vol. 35(13), pp. 2419 to 2439 (1992) Jacobs et al., J. Med. Chem., vol. 37(9), pp. 1282 to 1297 (1994); AU 646 587 Australia 3/1993; McFadden, E.R., Jr., Am Rev. Resp. Dis., vol. 147 pp. 1306-1310 (1993); Greenberger, P.A., Chest, vol. 101 pp. 418S-421S (1992); Lipworth, B.J. Pharmacol. Ther., vol. 58 pp. 173-209 (1993); Busse, W.W., Chest, vol. 104 pp. 1565-1571 (1993); Anonymous, Executive Summary: Guidelines for the Diagnosis and Management of Asthma, Public Health Service, Publication 91-3042A, NIH, Bethesda, MD., pp. 1-44 (1991); Israel, E., and Drazen, J.M., N. Engl. J. Med., vol.,

331 pp. 737-739 (1994); or Barnes, P.J., N. Engl. Med., vol. 332 pp. 868-875 (1995). All these prior publications are expressly incorporated by reference.

For purposes of the formulations of this invention, which are intended for inhalation into the lungs, the medicament or drug is preferably
5 micronized whereby a therapeutically effective amount or fraction (e.g., ninety percent or more) of the drug is particulate. Typically, the particles have a diameter of less than about 10 microns, and preferably less than about 5 microns, in order that the particles can be inhaled into the respiratory tract and/or lungs.

The particulate medicament or drug is present in the inventive
10 formulations in a therapeutically effective amount, that is, an amount such that the drug can be administered as an aerosol, such as topically, or via oral or nasal inhalation, and cause its desired therapeutic effect, typically preferred with one dose, or through several doses. The particulate drug is administered as an aerosol from a conventional valve, e.g., a metered dose valve.

15 The term "amount" as used herein refers to quantity or to concentration as appropriate to the context. The amount of a drug that constitutes a therapeutically effective amount varies according to factors such as the potency of the particular drug, the route of administration of the formulation, and the mechanical system used to administer the formulation. A therapeutically effective
20 amount of a particular drug can be selected by those of ordinary skill in the art with due consideration of such factors. Generally a therapeutically effective amount will be from about 0.001 parts by weight to about 2 parts by weight based on 100 parts by weight of the propellant.

A suitable propellant is selected. A suitable propellant is any
25 fluorocarbon, e.g. a 1-4 hydrogen containing fluorocarbon(, such as CHF_2CHF_2 , $\text{CF}_3\text{CH}_2\text{F}$, $\text{CH}_2\text{F}_2\text{CH}_3$ and $\text{CF}_3\text{CHF}(\text{CF}_3)$), a perfluorocarbon, e.g. a 1-4 carbon perfluorocarbon, (such as CF_3CF_3 , $\text{CF}_3\text{CF}_2\text{CF}_3$); or any mixture of the foregoing, having a sufficient vapor pressure to render them effective as propellants. Some typical suitable propellants include conventional chlorofluorocarbon (CFC)
30 propellants such as mixtures of propellants 11, 12 and 114. Non-CFC propellants such as 1,1,1,2-tetrafluoroethane (Propellant 134a), 1,1,1,2,3,3,3-heptafluoropropane (Propellant 227) or mixtures thereof are preferred. The propellant is preferably

present in an amount sufficient to propel a plurality of the selected doses of drug from an aerosol canister.

A suitable stabilizer is selected. A suitable stabilizer is a "water addition". As used herein a "water addition" is an amount of water which (1) is added, either initially with other components of the aerosol formulation, e.g. medicament and propellant, or after the other components, e.g. medicament, propellant, are combined and processed, (2) is in addition to the water which is always present and which develops during processing and/or storage of the aerosol formulation, i.e. "developed" or "nascent" formulation water, and (3) is present in an amount which stabilizes the ordinarily unstable medicinal aerosol formulation having nascent formulation water.

An aerosol formulation preferably comprises the water addition in an amount effective to stabilize the formulation relative to an identical formulation not containing the water addition, i.e. containing only nascent formulation water, such that the drug does not settle, cream or flocculate after agitation so quickly as to prevent reproducible dosing of the drug. Reproducible dosing can be achieved if the formulation retains a substantially uniform drug concentration for about two or three seconds after agitation.

The particular amount of the water addition that constitutes an effective amount is dependent upon the particular propellant and on the particular drug used in the formulation. It is therefore not practical to enumerate specific effective amounts for use with specific formulations of the invention, but such amounts can readily be determined by those skilled in the art with due consideration of the factors set forth above. Generally, however, the water addition must be present in a formulation in an amount in excess of the concentration of the nascent formulation water. Such concentration of nascent formulation water typically ranges up to 300 parts by weight per one million parts by weight of the total weight of the aerosol formulation. Accordingly, the water addition in excess of this nascent water concentration typically ranges from about 300 parts by weight to 2000 parts by weight per one million parts by weight of the total aerosol formulation weight. Most preferred is that the concentration of the water addition is from 500 parts by weight

to 700 parts by weight per one million parts by weight of the total weight of the medicinal aerosol formulation.

It is to be emphasized that this is an amount which exceeds the amount of nascent or developed formulation water. It is also to be stressed that this amount of water addition can be added and initially combined with the other components of the formulation, e.g. medicament, such as triamcinolone acetonide, and propellant, e.g. 1,1,1,2-tetrahydrofluoroethane, or added to the resultant formulation after these other components have been processed, e.g. prior to or subsequent to storage.

It has surprisingly been found that the formulation of the invention is stable without the necessity of employing a cosolvent, such as ethanol, or surfactants. However, further components, such as conventional lubricants or surfactants, cosolvents, ethanol, etc., can also be present in an aerosol formulation of the invention in suitable amounts readily determined by those skilled in the art. In this regard, reference is made to U.S. Patent No. 5,225,183, which is incorporated by reference hereinto in its entirety.

A most preferred formulation comprises the medicament, the propellant, the ethanol cosolvent and the water addition, for example, triamcinolone acetonide, budesonide, fluticasone, or mometasone, 1,1,1,2-tetrafluoroethane, ethanol and the water addition.

Generally the formulations of the invention can be prepared by combining (i) the drug in an amount sufficient to provide a plurality of therapeutically effective doses; (ii) the water addition in an amount effective to stabilize each of the formulations; (iii) the propellant in an amount sufficient to propel a plurality of doses from an aerosol canister; and (iv) any further optional components e.g. ethanol as a cosolvent; and dispersing the components. The components can be dispersed using a conventional mixer or homogenizer, by shaking, or by ultrasonic energy. Bulk formulation can be transferred to smaller individual aerosol vials by using valve to valve transfer methods, pressure filling or by using conventional cold-fill methods. It is not required that a stabilizer used in a suspension aerosol formulation be soluble in the propellant. Those that are not sufficiently soluble can be coated onto the drug particles in an appropriate amount

and the coated particles can then be incorporated in a formulation as described above.

Aerosol canisters equipped with conventional valves, preferably metered dose valves, can be used to deliver the formulations of the invention. It has been found, however, that selection of appropriate valve assemblies for use with aerosol formulations is dependent upon the particular stabilizer and other adjuvants used (if any), on the propellant, and on the particular drug being used. Conventional neoprene and buna valve rubbers used in metered dose valves for delivering conventional CFC formulations often have less than optimal valve delivery characteristics and ease of operation when used with formulations containing HFC-134a or HFC-227. Therefore certain formulations of the invention are preferably dispensed via a valve assembly wherein the diaphragm is made of a nitrile rubber such as DB-218 (American Gasket and Rubber, Schiller Park, Ill.) or an EPDM rubber such as Vistalon™ (Exxon), Royalene™ (UniRoyal), bunaEP (Bayer). Also suitable are diaphragms fashioned by extrusion, injection molding or compression molding from a thermoplastic elastomeric material such as FLEXOMER™ GERS 1085 NT polyolefin (Union Carbide).

Conventional aerosol canisters, coated or uncoated, anodized or unanodized, e.g., those of aluminum, glass, stainless steel, polyethylene terephthalate, and coated canisters or cans with epon, epoxy, etc., can be used to contain a formulation of the invention.

The formulation of the invention can be delivered to the respiratory tract and/or lung by oral inhalation in order to effect bronchodilation or in order to treat a condition susceptible of treatment by inhalation, e.g., asthma, chronic obstructive pulmonary disease. The formulations of the invention can also be delivered by nasal inhalation in order to treat, e.g., allergic rhinitis, rhinitis, (local) or diabetes (systemic), or they can be delivered via topical (e.g., buccal) administration in order to treat, e.g., angina or local infection.

Claims:

1. A medicinal aerosol formulation, which comprises:
 - (a) a therapeutically effective amount of a particulate medicament;
 - 5 (b) a propellant; and
 - (c) a stabilizer comprising a water addition present in an amount which (a) is in addition to nascent formulation water and (b) stabilizes the formulation.
2. The formulation as defined in claim 1 wherein said
10 medicament is selected from the group consisting of albuterol, atropine, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol, prednisone, mometasone, triamcinolone acetone, salmeterol, amiloride, fluticasone, (-)-4-amino-3,5-dichloro- α -[[[6-(2-pyridinyl)ethoxy] hexyl] amino] methyl]benzene-methanol and pharmaceutically
15 acceptable salts, esters, hydrates and solvates of the foregoing.
3. The formulation as defined in claim 2 wherein said medicament comprises triamcinolone acetone.
4. The formulation as defined in claim 1, wherein said propellant
is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-
20 heptafluoropropane or a mixture thereof.
5. The formulation as defined in claim 1 which further includes a cosolvent.
6. The formulation as defined in claim 5 wherein said cosolvent comprises ethanol.
- 25 7. The formulation as defined in claim 1 wherein said stabilizer is present in an amount effective to prevent settling, creaming or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.
8. The formulation as defined in claim 7 wherein said stabilizer
30 is present in an amount ranging from about 500 parts by weight to about 2000 parts weight based on 1 million parts by total weight of the formulation.

9. The formulation as defined in claim 8 wherein said stabilizer is present in an amount ranging from 500 parts by weight to 700 parts by weight to one million parts by total weight of the formulation.

10. A method of preparing a medicinal aerosol formulation according to claim 1, which comprises:

(a) combining (i) said medicament in an amount sufficient to provide a plurality of therapeutically effective doses, (ii) said propellant in an amount sufficient to propel a plurality of said therapeutically effective doses from an aerosol canister; and (iii) said stabilizer in an amount effective to stabilize the formulation; and

(b) dispersing components (i), (ii) and (iii).

11. The method as defined in claim 10 wherein the medicinal aerosol formulation further comprises combining in step (a) a cosolvent and in step (b) dispersing components (i), (ii), (iii) with said cosolvent.

12. A method of treating in an animal a condition capable of treatment by oral or nasal inhalation, which comprises, administering a formulation according to claim 1 to said animal by oral or nasal inhalation.

13. A formulation according to claim 1 in an aerosol canister equipped with a metered dose valve.

14. A method of stabilizing a suspension aerosol formulation comprising a propellant and a particulate drug, which comprises,

incorporating into the formulation a stabilizer comprising a suitable concentration of a water addition where said concentration is present in an amount which is effective to prevent settling, creaming, or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.

15. A metered dose inhaler containing a medicinal aerosol formulation, the formulation comprising:

(a) a drug in particulate form in a therapeutically effective amount;

(b) a propellant; and

(c) a stabilizer comprising a water addition which is present in an amount which (1) is in excess of nascent formulation water and (2) is present in an amount to stabilize the formulation to prevent settling, creaming or flocculation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.

16. The metered dose inhaler as defined in claim 15 wherein said stabilizer is present in an amount of 300 parts by weight to about 2000 parts by weight based on one million parts by total weight of the medicinal aerosol formulation.

17. The metered dose inhaler as defined in claim 16 wherein the drug is selected from the group consisting of albuterol, atropine, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol, prednisone, mometasone, triamcinolone acetate, salmeterol, amiloride, fluticasone, an ester of fluticasone, (-)-4-amino-3,5-dichloro- α -[[[6(2-pyridinyl)ethoxy] hexyl] amino] methyl]benzene-methanol and pharmaceutically acceptable hydrates, salts and solvates of the foregoing.

18. The metered dose inhaler as defined in claim 17 wherein the propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane or a mixture thereof.

19. The metered dose inhaler as defined in claim 18 wherein said medicament comprises triamcinolone acetate.

20. The metered dose inhaler as defined in claim 19 wherein said stabilizer is present in an amount ranging from 500 parts by weight to 700 parts by weight per one million parts by weight of the medicinal aerosol formulation.

21. The metered dose inhaler as defined in claim 20 wherein the medicinal aerosol formulation further comprises a cosolvent.

22. The metered dose inhaler as defined in claim 21 wherein said cosolvent comprises ethanol.

23. A medicinal aerosol formulation, which comprises:

(a) a therapeutically effective amount of a combination of at least two different particulate medicaments;

(b) a propellant; and

(c) a stabilizer comprising a water addition present in an amount which (a) is in addition to nascent formulation water and (b) stabilizes the formulation.

24. The formulation as defined in claim 23 wherein said
5 medicament is selected from the group consisting of albuterol, atropine, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol, prednisone, mometasone, triamcinolone acetonide, salmeterol, amiloride, fluticasone, (-)-4-amino-3,5-dichloro- α -[[[6(2-pyridinyl)ethoxy] hexyl] amino] methyl]benzene-methanol, acetoaminophen,
10 ibuprofen, the pharmaceutically acceptable salts, esters, hydrates and solvates optical or geometric isomers of the foregoing and mixtures of any of the foregoing medicaments.

25. The formulation as defined in claim 23, wherein the medicaments in the combination are selected from the group consisting of β -2
15 adrenergic agonists, corticosteroids, anticholinergics, histamine antagonists, non-steroidal antiinflammatory agents and leucotriene modulators.

26. The formulation as defined in claim 25, wherein the β -2 adrenergic agonists are albuterol, formoterol or the pharmaceutically acceptable salts, esters or the optical or geometric isomers of the foregoing.

27. The formulation as defined in claim 25, wherein the
20 corticosteroids are selected from the group consisting of mometasone, hydrocortisone, fludrocortisone, dexamethasone, prednisone, cortisone, aldosterone hemi-acetal, betametasone, beclomethasone dipropionate, triamcinolone acetonide, budesonide, dipropionate, fluticasone, flunisolide and the pharmaceutically
25 acceptable salts, esters, hydrates, solvates and optical or geometric isomers of the foregoing.

28. The formulation as defined in claim 25, wherein the anticholinergic is cromolyn, or the pharmaceutically acceptable salts or esters of the foregoing.

29. The formulation as defined in claim 25, wherein the
30 leucotriene modulator is selected from the group consisting of [[1-formyl-5-(cyclopentylloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-

tolylsulfonylbenzamide, [1-(hydroxycarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-((2-carboxyethyl)carbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-((2-tetrazolyethyl)carbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-(methylphenylcarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide; [1-(diphenylcarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide; [1-carbamoyl-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-(pyrrolidine-carbonyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, the pharmaceutically acceptable salts of the foregoing and mixtures of any of the foregoing medicaments.

30. The formulation as defined in claim 23, wherein the combination comprises a corticosteroid and a β -2 adrenergic agonist.

31. The formulation as defined in claim 23, wherein the combination comprises a corticosteroid and an anticholinergic agent.

32. The formulation as defined in claim 23, wherein the combination comprises a corticosteroid and a leucotriene modulator.

33. The formulation as defined in claim 23, wherein the combination comprises a corticosteroid, a β -2 adrenergic agonist and a leucotriene modulator.

34. The formulation as defined in claim 30, wherein the corticosteroid is fluticasone or fluticasone propionate.

35. The formulation as defined in claim 23 wherein the combination comprises a β -2 adrenergic agonist or a leucotriene modulator or a β -2 adrenergic agonist and an anticholinergic.

36. The formulation as defined in claim 23 wherein the combination comprises a non-steroidal antiinflammatory or a histamine antagonist.

37. The formulation as defined in claim 23 which further includes a cosolvent.

38. The formulation as defined in claim 37 wherein said cosolvent comprises ethanol.

39. The formulation as defined in claim 23 wherein said stabilizer is present in an amount effective to prevent settling, creaming or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.

40. A method of preparing a medicinal aerosol formulation according to claim 23, which comprises:

(a) combining (i) said combination of at least two different medicaments in an amount sufficient to provide a plurality of therapeutically effective doses, (ii) said propellant in an amount sufficient to propel a plurality of said therapeutically effective doses from an aerosol canister; and (iii) said stabilizer in an amount effective to stabilize the formulation; and

(b) dispersing components (i), (ii) and (iii).

41. The method as defined in claim 40 wherein the medicinal aerosol formulation further comprises combining in step (a) a cosolvent and in step (b) dispersing components (i), (ii), (iii) with said cosolvent.

42. A method of treating in an animal a condition capable of treatment by oral or nasal inhalation, which comprises, administering a formulation according to claim 23 to said animal by oral or nasal inhalation.

43. A formulation according to claim 23 in an aerosol canister equipped with a metered dose valve.

44. A method of stabilizing a suspension aerosol formulation comprising a propellant and a particulate drug, which comprises, incorporating into the formulation a stabilizer comprising a suitable concentration of a water addition where said concentration is present in an amount which is effective to prevent settling, creaming, or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.

45. A metered dose inhaler containing a medicinal aerosol formulation, the formulation comprising:

(a) a combination of at least two different drugs in particulate form in a therapeutically effective amount;

(b) a propellant; and

(c) a stabilizer comprising a water addition which is present in an amount which (1) is in excess of nascent formulation water and (2) is present in an amount to stabilize the formulation to prevent settling, creaming or flocculation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.

46. A medicinal aerosol formulation, which consists essentially of:

(a) a therapeutic effective amount of a combination of at least two different particulate medicaments;

(b) a propellant; and

(c) a stabilizer consisting of water, in addition to nascent water present in the formulation, in an amount ranging from about 300 parts by weight to about 2000 parts by weight to one million parts by total weight of the formulation.

47. A medicinal aerosol formulation which consists essentially of

(a) a therapeutic effective amount of a combination of at least two different particulate medicaments;

(b) a propellant; and

(c) a stabilizer consisting of water, in addition to nascent water present in the formulation, in an amount ranging from about 300 parts by weight to about 2000 parts by weight to one million parts by weight to one million parts by total weight of formulation, which is obtained by:

(a) either:

i) combining said medicaments, propellant and water;
or

ii) combining said medicaments and propellant followed by the addition of water; and

(b) dispersing the medicaments, propellant and water.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07672 A3

- (51) International Patent Classification⁷: **A61K 9/12**
- (21) International Application Number: **PCT/US00/42625**
- (22) International Filing Date: **7 December 2000 (07.12.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
09/619,183 **19 July 2000 (19.07.2000)** **US**
- (71) Applicant: **AEROPHARM TECHNOLOGY, INC.**
[—/US]; Raritan Center, Campus Plaza, 18 Mayfield Avenue, Edison, NJ 08837 (US).
- (72) Inventors: **ADJEL, Akwete, L.**; 15 Tillman Court, Bridgewater, NJ 08807 (US). **CUTIE, Anthony, J.**; 10 Tillman Court, Bridgewater, NJ 08807 (US).
- (74) Agent: **ROSENSTOCK, Jerome**; Frommer Lawrence & Haug LLP, 745 Fifth Avenue, New York, NY 10151 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— *with international search report*
- (88) Date of publication of the international search report:
27 June 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/07672 A3

(54) Title: **A MEDICINAL AEROSOL FORMULATION**

(57) Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, or combination of at least two particulate drugs a propellant and a stabilizing agent comprising a water addition.

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US00/42625

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 9/12 US CL : 424/45 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/45 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	US 6,136,294 A (ADJEI et al.) 24 October 2000, see entire document	1-47		
Y	US 5,676,931 A (ADJEI et al.) 14 October 1997, see entire document.	1-47		
Y	US 5,674,471 A (Akehurst et al.) 7 October 1997, see entire document.	1-47		
Y	US 5,225,183 A (Purewal et al.) 6 July 1993, see entire document.	1-47		
Y	US 5,695,744 A (Neale et al.) 9 December 1997, see entire document.	1-47		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family			
Date of the actual completion of the international search 31 JANUARY 2002		Date of mailing of the international search report 04 APR 2002		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 505-3930		Authorized officer <i>Felicia D. Roberts for</i> RAJ BAWA, Ph.D. Telephone No. (703) 508-2423		